<DOC>
	<DOCNO>NCT00791622</DOCNO>
	<brief_summary>The purpose study 1 ) determine whether effect QT interval correct ( QTcLD ) heart rate use population specify linear derive method steady state comparable 12 mg paliperidone extended-release ( ER ) daily 400-mg quetiapine administer twice daily , 2 ) explore relationship pharmacokinetics paliperidone ER electrocardiogram ( ECG ) parameter interest , 3 ) explore cardiovascular safety tolerability 18 mg paliperidone ER steady state , 4 ) evaluate safety tolerability treatment .</brief_summary>
	<brief_title>A Study QT QTc Intervals Patients Administered Extended Release Paliperidone Quetiapine</brief_title>
	<detailed_description>This multicenter , placebo- positive-controlled , randomize study consist 3 phase - screen phase 5 day , 6-day placebo washout phase , treatment phase include 1-day open-label moxifloxacin treatment ( Day 1 ) , 10 day double-blind treatment ( Days 2 11 ) , end study evaluation ( Day 12 ) . On Day 1 , patient receive open-label treatment single dose 400 mg moxifloxacin administer morning . Moxifloxacin use establish assay sensitivity QTc interval . Patients randomly assign receive double-blind treatment placebo , paliperidone ER , quetiapine Days 2 11 . Two dose paliperidone ER study : 12 mg/day maximum recommend dose 18 mg/day supratherapeutic dose ( 50 % maximum recommend ) . Patients randomly assign paliperidone ER administer 12 mg Days 2 6 , 15 mg Day 7 , 18 mg Days 8 11 . Patients randomly assign quetiapine receive 100 mg bid Day 2 , 200 mg twice daily ( bid ) Day 3 , 300 mg bid Day 4 , 400 mg bid Days 5 11 . Patients receive double-blind study drug 30 minute standardize breakfast Days 2 11 . Serial time match 12 lead ECG triplicate reading record Days -2 , -1 , 6 , 11 ( predose 1 , 1.5 , 2.5 , 3.5 , 4.5 , 6 , 12 hour postdose ) well Day 1 ( predose , 1 , 1.5 , 2.5 , 3.5 hour postdose ) Days 7 12 ( 23.5 hour postdose ) . This study explore QTc pharmacokinetic data paliperidone ER ( commercial formulation ) quetiapine ( marketed atypical antipsychotic therapeutic class ) maximum recommend dos product supratherapeutic dose ( 50 % maximum propose label dose ) paliperidone ER . Safety tolerability monitor throughout study . A single oral dose moxifloxacin 400 mg tablet Day 1 ; Oral paliperidone ER 12 mg Days 2 6 ; 15 mg Day 7 , 18 mg Days 8 11 ; Oral quetiapine 100 mg twice daily ( bid ) Day 2 ; 200 mg bid Day 3 ; 300 mg bid Day 4 ; 400 mg bid Days 5 11 .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnosis schizophrenia schizoaffective disorder define DSMIVTR criterion , stable symptom . Symptom stability base clinical judgment investigator include minimum : exacerbation psychotic symptom psychiatric hospitalization least 3 month screen CGIS score &lt; =4 ( moderate ) screen Day 1 Must normal 12lead ECG screening Days 1 2 , include : Normal sinus rhythm ( heart rate 50 100 beat per minute QTcB interval &lt; = 430 millisecond men , &lt; = 450 millisecond woman QRS interval &lt; 110 millisecond PR interval &lt; 200 millisecond Must weigh &gt; = 50 kg ( &gt; = 110 lb ) , BMI &gt; = 18 &lt; = 35 kg/m2 If female , must postmenopausal least 2 year , surgically sterile , abstinent , agree practice effective method birth control sexually active entry throughout study . Effective method birth control include : abstinence , prescription oral contraceptive , contraceptive injection , intrauterine device , double barrier method , contraceptive patch , male partner sterilization . Women childbearing potential must negative serum pregnancy test screen negative urine pregnancy test baseline receive dose study drug Meets DSMIV criterion substance dependence 3 month screen Is risk suicidal violent behavior , judge investigator Has clinically significant abnormality ECG screening Days 2 1 study Has heart rhythm disturbance know suggested history demonstrate ECG screening , Days 2 1 study Has blood pressure outside normal range ( supine systolic blood pressure &lt; 90 &gt; 140 mmHg diastolic blood pressure &lt; 60 &gt; 90 mmHg ) Has unusual Twave morphology majority lead ECG ( bifid T wave , low T wave ) prominent U wave screen Has history additional risk factor torsade de pointes , heart failure , hypokalemia , family history know short long QT syndrome , sudden unexplained death young age ( &lt; = 40 year ) firstdegree relative ( i.e. , biological parent , sibling , offspring ) Has relevant history significant and/or unstable cardiovascular , respiratory ( include bronchial asthma ) , neurologic ( include seizure significant cerebrovascular disease ) , renal , hepatic , endocrine , immunologic , ophthalmologic , hematologic , systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Paliperidone ER</keyword>
	<keyword>Schizophernia</keyword>
	<keyword>Mood Disorders , Antipsychotic drug</keyword>
	<keyword>Cardiovascular</keyword>
	<keyword>Schizoaffective Disorder</keyword>
</DOC>